
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a prescriber's order for one patient. Not FDA-approved.
This is a compounded otic solution containing boric acid, prepared to a prescriber's order for one patient. Compounded preparations are not FDA-approved.
These listings cover every salt or ester form of each drug in the FDA National Drug Code Directory.
No FDA-approved (NDA or ANDA) product containing boric acid is listed. Products containing it are filed in the directory as homeopathic products and over-the-counter monograph drugs, in liquid, gel, suppository and spray forms. None of the listed products containing boric acid is in solution form.
Liquid bases can be aqueous or nonaqueous, and USP <795> classifies the preparation by its water activity. Aqueous preparations carry shorter default beyond-use dates than nonaqueous ones. The date printed on the label is the one to follow.
Compounded drugs are not FDA-approved. This means that FDA does not review these drugs to evaluate their safety, effectiveness, or quality before they reach patients.
Boric acid is a weak acid with antiseptic and antifungal properties, commonly compounded into vaginal capsules and suppositories.
Boric acid is a simple inorganic compound used medically as a topical antiseptic against bacteria and fungi. Marketed vaginal products describe it as returning vaginal pH to normal, and it has long been used for vaginal yeast infections that resist other treatments. No FDA-approved drug contains boric acid as its active ingredient. The products sold over the counter as vaginal suppositories are marketed as unapproved homeopathic drugs, and DailyMed carries the FDA statement that such products have not been evaluated for safety or efficacy. Boric acid also appears in some eye washes and animal products. Prescribers order boric acid compounded, most often as vaginal gelatin capsules, when they want a pharmacy-prepared product at a defined strength rather than a homeopathic OTC item, or a combination with another vaginal active. Compounded preparations are not FDA-approved and require a prescription.
Boric acid is poisonous if swallowed. Vaginal products carry the warning "for vaginal use only, not for oral consumption," and MedlinePlus describes poisoning symptoms that include blue-green vomiting, diarrhea, a bright red rash, drowsiness, seizures and collapse; infants have historically had high death rates from exposure. Keep every capsule away from children and pets, and if one is swallowed call Poison Control at 1-800-222-1222 right away. Do not use it with vaginal bleeding, sores, fever, pelvic pain or a suspected STI without asking a prescriber, and avoid intercourse during treatment; it is unknown whether boric acid damages latex condoms. Vaginal absorption is about 6 percent, far more than through intact skin. Pregnancy: OTC labels say ask a doctor first, and the drugs.com pregnancy page lists use as contraindicated. Breastfeeding: no milk data; e-lactancia rates it as limited compatibility and the drugs.com page lists use as contraindicated. Side effects are usually local burning, watery discharge and redness. Talk to your prescriber or pharmacist if symptoms worsen or persist.
Boric acid is a weak acid used vaginally as an antiseptic; its antifungal mechanism is not well defined in the cited literature. Vaginal absorption is roughly 6 percent and transdermal absorption through intact skin about 0.2 percent (e-lactancia, citing Prutting 1998 and ATSDR 2010); boric acid is excreted renally. No FDA-approved boric acid drug product exists, so there is no labeled indication; OTC vaginal suppositories are marketed as unapproved homeopathic drugs. Prescribers have ordered compounded boric acid vaginal capsules for recurrent and non-albicans vulvovaginal candidiasis: the CDC STI treatment guidelines describe boric acid in a gelatin capsule administered vaginally for recurrent non-albicans VVC, with clinical and mycologic eradication rates of about 70 percent, and a 2011 systematic review of 14 studies reported mycologic clearance rates of 40 to 100 percent with vaginal burning in under 10 percent of cases. Dosing is per prescriber. Monitoring: confirm the diagnosis and species when azole therapy fails, counsel on strict vaginal-only use and child-resistant storage, and reassess if symptoms persist. Not a controlled substance.
Wash your hands. Warm the bottle in your hand for a few minutes, since cold drops can cause dizziness. Lie on your side or tilt your head so the affected ear faces up. Pull the ear up and back (back and down for a young child) and place the number of drops on your label into the canal without touching the dropper tip to your ear. Stay in position for a few minutes. Recap and wash your hands. Do not use drops that have changed color or turned cloudy.
Otic solutions are aqueous or glycerin based. Under USP <795>, a preserved aqueous solution usually carries a beyond-use date of up to 35 days; an unpreserved one 14 days refrigerated; a nonaqueous solution may carry up to 180 days. Follow the storage line on your label, keep out of reach of children, and discard after the beyond-use date.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Place drops into affected ear(s)